managerial or professional time, $20 for skilled technical time, and $10 for clerical time) are averages.

Recordkeeping: For the 1,000,000 recordkeeping hours, staff estimates that 10 percent of the burden hours require skilled technical time and 90 percent require clerical time. As shown below, the total recordkeeping cost is $11,000,000.

Disclosure: For each notice or information item listed, staff estimates that 10 percent of the burden hours require managerial time and 90 percent require skilled technical time. As shown below, the total disclosure cost is $447,877,068.

Required task	Managerial		Skilled technical		Clerical		Total cost ($)
	Time (hours)	Cost ($50/hr.)	Time (hours)	Cost ($20/hr.)	Time (hours)	Cost (10/hr.)	
Recordkeeping	0	0	100,000	$2,000,000	900,000	$9,000,000	$11,000,000
Open-end credit Disclosures:							
Initial terms	25,833	$1,291,665	232,500	$4,649,994	0	0	$5,941,659
Rescission notices	2,542	127,085	22,875	457,506	0	0	584,491
Change in terms	29,583	1,479,165	266,250	5,324,994	0	0	6,804,159
Periodic statements	510,000	25,500,000	4,590,000	91,800,000	0	0	117,300,000
Error resolution	88,333	4,416,665	795,000	15,899,994	0	0	20,316,659
Credit and charge card accounts	30,833	1,541,665	277,500	5,549,994	0	0	7,091,659
Home equity lines of credit	12,083	604,165	108,750	2,174,994	0	0	2,779,159
Advertising	6,833	341,665	61,500	1,229,994	0	0	1,571,659
Total open-end credit							162,389,545
Closed-end credit Disclosures:							
Credit disclosures	1,140,000	57,000,000	10,260,000	205,200,000	0	0	262,200,000
Rescission notices	66,667	3,333,335	600,000	12,000,006	0	0	15,333,341
Variable rate mortgages	11,000	550,000	99,000	1,980,000	0	0	2,530,000
High rate/high fee mortgages	6,667	333,335	60,000	1,200,006	0	0	1,533,341
Reverse mortgages	2,750	137,500	24,750	495,000	0	0	632,500
Advertising	14,167	708,335	127,500	2,550,006	0	0	3,258,341
Total closed-end credit							285,487,523
Total Disclosures							447,877,068
Total Recordkeeping and Disclosures:							458,877,068

(Minor discrepancies in totals are due to rounding of the hours shown for skilled technical time.)

Debra A. Valentine,

General Counsel.

[FR Doc. 99–33206 Filed 12–21–99; 8:45 am]

BILLING CODE 6750–01–M

GENERAL SERVICES ADMINISTRATION

President's Commission on the Celebration of Women in American History

AGENCY: General Services Administration.

ACTION: Meeting notice.

SUMMARY: Notice is hereby given that the President's Commission on the Celebration of Women in American History will hold an open meeting from 9 a.m. to 4 p.m. on Tuesday, January 18, 2000, at the New York Public Library, 5th Avenue & 42 Street, New York, NY 10018.

PURPOSE: To hear testimony about the Year 2000 Celebration plans for Women's History Month and review current related activities.

Guest speakers will address the National Women's History Month celebration to be held in Washington on March 22 and review the status of the Commissions' recommendations for action for the year 2000.

Participants may wish to make a statement covering personal interests in the history of women in America or share thoughts on appropriate commemorative events.

FOR FURTHER INFORMATION CONTACT: Martha Davis (202) 501–0705, Assistant to the Associate Administrator for Communications, General Services Administration. Also, inquiries may be sent to *martha.davis@gsa.gov.*

Dated: December 14, 1999.

Beth Newburger,

Associate Administrator for Communications.

[FR Doc. 99–33116 Filed 12–21–99; 8:45 am]

BILLING CODE 6820–34–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 99F–5321]

United States Department of Agriculture, Food Safety and Inspection Service; Filing of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that the United States Department of Agriculture, Food Safety and Inspection Service (USDA/FSIS) has filed a petition proposing that the food additive regulations be amended to provide for the safe use of a 4.5 kiloGray (kGy) maximum dose of ionizing radiation to treat unrefrigerated (as well as refrigerated) uncooked meat, meat products, and certain meat food products to reduce levels of foodborne pathogens and extend shelf-life.

FOR FURTHER INFORMATION CONTACT: Rudaina H. Alrefai, Center for Food Safety and Applied Nutrition (HFS–206), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–418–3034.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5) (21 U.S.C. 348(b)(5))), notice is given that a food additive petition (FAP 9M4695) has been filed by the USDA/FSIS, 300 12th St. SW., rm. 112, Washington, DC 20250. The petition proposes that the food additive regulations in § 179.26(b) Ionizing radiation for the treatment of food (21 CFR 179.26(b)) be amended to provide for the safe use of a 4.5 kGy maximum dose of ionizing radiation to treat unrefrigerated (as well as refrigerated) uncooked meat, meat products, and certain meat food products to reduce levels of foodborne pathogens and extend shelf-life. The current regulations in § 179.26(b) provide for the use of a maximum dose of 4.5 kGy to treat refrigerated products only.

The agency has determined under 21 CFR 25.32(j) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

Dated: December 3, 1999.

Alan M. Rulis,

Director, Office of Premarket Approval, Center for Food Safety and Applied Nutrition.

[FR Doc. 99–33093 Filed 12–21–99; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Microbiology Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA).

Name of Committee: Microbiology Devices Panel of the Medical Devices Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA's regulatory issues.

Date and Time: The meeting will be held on January 20, 2000, 9:45 a.m. to 6:30 p.m., and January 21, 2000, 8 a.m. to 4:30 p.m.

Location: Corporate Bldg., conference rm. 020B, 9200 Corporate Blvd., Rockville, MD.

Contact: Freddie M. Poole, Center for Devices and Radiological Health (HFZ–440), Food and Drug Administration, 2098 Gaither Rd., Rockville, MD 20850, 301–594–2096, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 12517. Please call the Information Line for up-to-date information on this meeting.

Agenda: On January 20, 2000, the committee will discuss, make recommendations, and vote on six premarket approval applications (PMA's) for in vitro diagnostic qualitative devices to detect hepatitis B serological markers in human sera or plasma. The following hepatitis B serological marker assays, when used appropriately in combination, are indicated as an aid in the diagnosis and monitoring of disease and therapy in acute and chronic hepatitis B virus infection (HBV) in both low and high risk adult populations:

1. Hepatitis B surface antigen (HBsAg) (HBsAg assay may be used alone as an indicator of HBV infection when performing prenatal testing);

2. Antibodies to hepatitis B surface antigen (anti-HBs) (anti-HBs assay may be used alone to determine the immune status of HBV vaccine recipients);

3. Hepatitis B e antigen (HBeAg);

4. Antibodies to hepatitis B e antigen (anti-HBe);

5. Hepatitis B core antigen (anti-HBc); and

6. Immunoglobulin M antibodies to hepatitis B core antigen (IgM anti-HBc).

These tests are not intended for blood donor screening.

Also, on January 20, 2000, the committee will discuss and make recommendations on issues concerning the use of characterized hepatitis panels in assessing the performance of in vitro diagnostic devices for the determination of hepatitis infection as an alternative to conducting intensive prospective clinical trials.

The following draft questions are proposed for discussion and may be subject to changes prior to the committee meeting:

1. Will the use of characterized hepatitis panels provide assurance of the safety and effectiveness of the assay in various populations?

2. What criteria should be used to include specimens in these panels?

3. Will panels be sufficient to support claims for the diagnosis of HBV infection or immunity for all indicated populations?

4. Who should control panel distribution and evaluation, e.g., device manufacturers, FDA, or an independent third party?

FDA will consider these recommendations in the future development of review criteria for in vitro diagnostic devices, for the detection of hepatitis antigen or antibodies to hepatitis antigen, as valid scientific evidence to determine whether there is reasonable assurance that these devices are safe and effective.

On January 21, 2000, the committee will discuss, make recommendations, and vote on a PMA for an in vitro diagnostic qualitative device for the detection of antibody to hepatitis C virus in human serum or plasma. This device is not intended for use in blood or plasma donor screening.

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by January 12, 2000. On January 20, 2000, oral presentations from the public will be scheduled between approximately 12 noon and 12:30 p.m., 3 p.m. and 3:30 p.m., and 5:30 p.m. and 6 p.m. On January 21, 2000, oral presentations from the public will be scheduled between approximately 11:30 a.m. and 12:15 p.m., and 3:30 p.m. and 4 p.m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before January 12, 2000, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: December 13, 1999.

Linda A. Suydam,

Senior Associate Commissioner.

[FR Doc. 99–33122 Filed 12–21–99; 8:45 am]

BILLING CODE 4160–01–F